Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Management of Immunotherapy-Related Toxicities, Version 1.2022, NCCN Clinical Practice Guidelines in Oncology
John A. Thompson, Bryan J. Schneider, Julie R. Brahmer, et al.
Journal of the National Comprehensive Cancer Network (2022) Vol. 20, Iss. 4, pp. 387-405
Open Access | Times Cited: 303

Showing 1-25 of 303 citing articles:

Update 2020: Management of Non-Small Cell Lung Cancer
Mariam Alexander, So Yeon Kim, Haiying Cheng
Lung (2020) Vol. 198, Iss. 6, pp. 897-907
Open Access | Times Cited: 465
Drug allergy: A 2022 practice parameter update
David A. Khan, Aleena Banerji, Kimberly G. Blumenthal, et al.
Journal of Allergy and Clinical Immunology (2022) Vol. 150, Iss. 6, pp. 1333-1393
Open Access | Times Cited: 265
Sintilimab Plus Chemotherapy for Unresectable Gastric or Gastroesophageal Junction Cancer
Jianming Xu, Haiping Jiang, Yueyin Pan, et al.
JAMA (2023) Vol. 330, Iss. 21, pp. 2064-2064
Open Access | Times Cited: 125
Association of Immune-Related Adverse Events With Efficacy of Atezolizumab in Patients With Non–Small Cell Lung Cancer
Mark A. Socinski, Robert M. Jotte, Federico Cappuzzo, et al.
JAMA Oncology (2023) Vol. 9, Iss. 4, pp. 527-527
Open Access | Times Cited: 119
Current landscape and future directions of bispecific antibodies in cancer immunotherapy
Jing Wei, Yueyao Yang, Gang Wang, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 102
Immune Checkpoint Inhibitor Therapy in Oncology
Sean Tan, Daphne Day, Stephen J. Nicholls, et al.
JACC CardioOncology (2022) Vol. 4, Iss. 5, pp. 579-597
Open Access | Times Cited: 94
Racial and Ethnic Disparities in Cervical Cancer Incidence, Survival, and Mortality by Histologic Subtype
Camryn M. Cohen, Nicolas Wentzensen, Philip E. Castle, et al.
Journal of Clinical Oncology (2022) Vol. 41, Iss. 5, pp. 1059-1068
Open Access | Times Cited: 79
Immunotherapy in hematologic malignancies: achievements, challenges and future prospects
Lu Tang, Zhongpei Huang, Heng Mei, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 53
Current understanding and management of CAR T cell-associated toxicities
Jennifer N. Brudno, James N. Kochenderfer
Nature Reviews Clinical Oncology (2024) Vol. 21, Iss. 7, pp. 501-521
Closed Access | Times Cited: 47
Consensus recommendations on the management of toxicity associated with CD3×CD20 bispecific antibody therapy
Jennifer L. Crombie, Tara Graff, Lorenzo Falchi, et al.
Blood (2024) Vol. 143, Iss. 16, pp. 1565-1575
Open Access | Times Cited: 46
Selective immune suppression using interleukin-6 receptor inhibitors for management of immune-related adverse events
Faisal Fa’ak, Maryam Buni, Adewunmi Falohun, et al.
Journal for ImmunoTherapy of Cancer (2023) Vol. 11, Iss. 6, pp. e006814-e006814
Open Access | Times Cited: 45
Immune-Related Adverse Events of Immune Checkpoint Inhibitors
Manuel Ramos‐Casals, Antoni Sisó‐Almirall
Annals of Internal Medicine (2024) Vol. 177, Iss. 2, pp. ITC17-ITC32
Closed Access | Times Cited: 23
PD-1/PD-L1 inhibitors related adverse events: A bibliometric analysis from 2014 to 2024
Qingya Song, Zongliang Yu, Wenping Lü, et al.
Human Vaccines & Immunotherapeutics (2025) Vol. 21, Iss. 1
Open Access | Times Cited: 2
Immune-related adverse events in older adults receiving immune checkpoint inhibitors: a comprehensive analysis of the Food and Drug Administration Adverse Event Reporting System
Buğra Han Esen, Şevval Nur Bektaş, A. Umur Topçu, et al.
Age and Ageing (2025) Vol. 54, Iss. 1
Open Access | Times Cited: 2
Effect of granulocyte colony-stimulating factor on toxicities after CAR T cell therapy for lymphoma and myeloma
Kevin C. Miller, P. Connor Johnson, Jeremy S. Abramson, et al.
Blood Cancer Journal (2022) Vol. 12, Iss. 10
Open Access | Times Cited: 44
How I treat unique and difficult to manage cases of CAR T-cell therapy associated neurotoxicity
Bianca Santomasso, Juliane Gust, Fabiana Perna
Blood (2023)
Open Access | Times Cited: 37
Overcoming Barriers to Referral for Chimeric Antigen Receptor T Cell Therapy in Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma
Marc Hoffmann, Bradley D. Hunter, Patrick Cobb, et al.
Transplantation and Cellular Therapy (2023) Vol. 29, Iss. 7, pp. 440-448
Open Access | Times Cited: 37
CAR-T cell therapy: Where are we now, and where are we heading?
Jiayi Wang, Liang Wang
Blood Science (2023) Vol. 5, Iss. 4, pp. 237-248
Open Access | Times Cited: 25
Steroid-Refractory Immune-Related Adverse Events Induced by Checkpoint Inhibitors
Dirk Tomsitz, Theresa Ruf, Sarah Zierold, et al.
Cancers (2023) Vol. 15, Iss. 9, pp. 2538-2538
Open Access | Times Cited: 22
Single-cell profiling identifies IL1Bhi macrophages associated with inflammation in PD-1 inhibitor-induced inflammatory arthritis
Ziyue Zhou, Xiaoxiang Zhou, Xu Jiang, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 14
Cardiovascular toxicities of immune therapies for cancer – a scientific statement of the Heart Failure Association (HFA) of the ESC and the ESC Council of Cardio‐Oncology
Carlo G. Tocchetti, Dimitrios Farmakis, Yvonne Koop, et al.
European Journal of Heart Failure (2024) Vol. 26, Iss. 10, pp. 2055-2076
Closed Access | Times Cited: 13
Preclinical development of novel PD-L1 tracers and first-in-human study of [68Ga]Ga-NOTA-RW102 in patients with lung cancers
You Zhang, Min Cao, Yanfei Wu, et al.
Journal for ImmunoTherapy of Cancer (2024) Vol. 12, Iss. 4, pp. e008794-e008794
Open Access | Times Cited: 11
Clinical Management of Patients With Relapsed/Refractory Multiple Myeloma Treated With Talquetamab
Ajai Chari, Amrita Krishnan, Leo Rasche, et al.
Clinical Lymphoma Myeloma & Leukemia (2024) Vol. 24, Iss. 10, pp. 665-693.e14
Open Access | Times Cited: 10
Cardiovascular toxicity of immune therapies for cancer
Nicolas L. Palaskas, Hyeon-Ju Ali, Efstratios Koutroumpakis, et al.
BMJ (2024), pp. e075859-e075859
Closed Access | Times Cited: 8
Grade ≥ 3 hematologic adverse events of immunotherapy in advanced NSCLC patients: a systematic review and meta-analysis
Shuang Wang, Meng‐Ting Cai, Yajun Xiong, et al.
European Journal of Clinical Pharmacology (2025)
Closed Access | Times Cited: 1
Page 1 - Next Page

Scroll to top